Kyverna Therapeutics (KYTX) Corporate presentation summary

Transformative therapy overview

• Miv-cel is a single-dose, fully human autologous CD19 CAR T therapy designed to reset the immune system and achieve durable, drug-free remission in neurologic autoimmune diseases.

• Demonstrated deep and broad depletion of B cells, robust CNS penetration, and upregulation of regulatory T cells, supporting broad immune reset.

• Over 100 patients dosed across multiple indications, with no high-grade CRS or ICANS observed.

Market opportunity and strategy

• SPS and gMG represent significant market opportunities, with ~6,000 SPS and ~80,000 gMG diagnosed patients in the U.S.

• SPS launch targets ~10 high-value centers, leveraging commercial CAR T experience and strong referral networks.

• Dual-source U.S. manufacturing strategy with >98% success rate and biologics-like margins.

• Commercial readiness underway, supporting premium pricing potential and efficient scaling to gMG and PMS.

Clinical efficacy in SPS

• SPS registrational trial (KYSA-8) met primary endpoint: 46% median improvement in T25FW at week 16 (P=0.0003); 81% achieved ≥20% improvement.

• All secondary endpoints showed significant improvements in disability, mobility, stiffness, and hypersensitivity (P<.0001).

• 67% of patients using walking aids at baseline no longer needed assistance at week 16.

• 100% of patients remained free of immunomodulatory or immunosuppressant therapies for SPS at week 16.

• Substantial improvements in physical and mental functioning, with 89-meter median improvement in 6-minute walk test.